Abstract
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Current Pharmaceutical Design
Title: PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Volume: 15 Issue: 30
Author(s): D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli and C. Pourzitaki
Affiliation:
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Abstract: PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Export Options
About this article
Cite this article as:
Kouvelas D., Goulas A., Papazisis G., Sardeli C. and Pourzitaki C., PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206971
DOI https://dx.doi.org/10.2174/138161209789206971 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Malformations of the Female Genital Tract and Embryological Bases
Current Women`s Health Reviews Prevention of Contrast Induced Nephropathy
Current Drug Therapy Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Protein & Peptide Letters Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Current Gene Therapy Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects
Drug Metabolism Letters Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs
Current Medicinal Chemistry Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Role of Perindopril in the Prevention of Stroke
Recent Patents on Cardiovascular Drug Discovery Biomarkers of Acute Kidney Injury in Critical Care Medicine: A Literature Review Based on Recent Patent Applications
Recent Patents on Biomarkers Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design The Use of Major Analgesics in Patients with Renal Dysfunction
Current Drug Targets Cardiovascular effect of Nigella sativa L. Aqueous Extract in Normal Rats
Cardiovascular & Hematological Disorders-Drug Targets Ionophores as Potent Anti-malarials: A Miracle in the Making
Current Topics in Medicinal Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued)